

NOT A USPTO FORM INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-15439	Serial No 10/577967
	First Applicant Robert Peter Gajewski	
	International Application Date: 8 November 2004	Group Art Unit 1621
	US Nat'l Entry Date: 2 May 2006	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AE	US 6,706,725	March 16, 2004	Bernardon	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)				
	BI					

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
	CJ	Basak, et al., "Comparative effects of calcipotriol and betamethasone 17-valerate solution in the treatment of seborrhoeic dermatitis of the scalp," <u>European Academy of Dermatology and Venereology JEADV</u> , Vol. 15, pgs. 77-92 (2001)	
	CK	Böhm, et al., "Disseminated superficial actinic porokeratosis: Treatment with topical tacalcitol," <u>Journal of the American Academy of Dermatology</u> , Vol. 40, pgs. 479-480 (1999)	
	CL	Cunningham, et al., "Topical calcipotriene for morphea/linear scleroderma," <u>Journal of the American Academy of Dermatology</u> , Vol. 39, pgs. 211-215 (1998)	
	CM	Harrison, "Disseminated superficial actinic porokeratosis responding to calcipotriol," <u>Clinical Exp. Dermatol.</u> , Vol. 19, No. 1, pg. 95 (1994)	
	CN	Lin, et al., "The pleiotropic actions of vitamin D," <u>BioEssays</u> , Vol. 26, pgs. 21-28 (2003)	
	CO	Nakayama, et al., "Four cases of sebopsoriasis or seborrhoeic dermatitis of the face and scalp successfully treated with 1a-24(R)-dihydroxycholecalciferol (tacalcitol) cream," <u>European Journal of Dermatology</u> , Vol. 10, No. 7, pgs. 528-532, (2000)	
	CP	Sapadin, et al., "Treatment of Scleroderma," <u>Arch Dermatology</u> , Vol. 138, pgs. 99-105 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

NOT A USPTO FORM INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Atty. Docket No. X-15439	Serial No 10/577967
		First Applicant Robert Peter Gajewski	
		International Application Date: 8 November 2004	Group Art Unit 1621
		US Nat'l Entry Date: 2 May 2006	
CQ	Sato, et al., "Epidermal Growth Factor and 1 α ,25-Dihydroxyvitamin D ₃ Suppress Kipogenesis in Hamster Sebaceous Gland Cells <i>In Vitro</i> ," <u>The Society of Investigative Dermatology</u> , Vol. 117, pgs. 965-970 (2001)		
CR	Zinser, et al., "Vitamin D ₃ receptor ablation sensitizes skin to chemically induced tumorigenesis," <u>Carcinogenesis</u> , Vol. 23, No. 12, pgs. 2103-2109 (2002)		

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.
Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.